MAIA Non Current Liabilities Total from 2010 to 2024
| MAIA Stock | USD 2.09 0.01 0.48% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 2.2 M | Current Value 2.3 M | Quarterly Volatility 767.3 K |
Check MAIA Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MAIA Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9, Interest Expense of 6.5 K or Selling General Administrative of 6.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 34.12. MAIA financial statements analysis is a perfect complement when working with MAIA Biotechnology Valuation or Volatility modules.
MAIA | Non Current Liabilities Total |
Latest MAIA Biotechnology's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of MAIA Biotechnology over the last few years. It is MAIA Biotechnology's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MAIA Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
MAIA Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 442,567 | |
| Geometric Mean | 105,465 | |
| Coefficient Of Variation | 173.38 | |
| Mean Deviation | 569,490 | |
| Median | 35,172 | |
| Standard Deviation | 767,332 | |
| Sample Variance | 588.8B | |
| Range | 2.2M | |
| R-Value | 0.73 | |
| Mean Square Error | 298.9B | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 124,742 | |
| Total Sum of Squares | 8.2T |
MAIA Non Current Liabilities Total History
About MAIA Biotechnology Financial Statements
MAIA Biotechnology stakeholders use historical fundamental indicators, such as MAIA Biotechnology's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although MAIA Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in MAIA Biotechnology's assets and liabilities are reflected in the revenues and expenses on MAIA Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MAIA Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 2.2 M | 2.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out the analysis of MAIA Biotechnology Correlation against competitors. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.